Cancer Immunology, Immunotherapy

, Volume 55, Issue 10, pp 1209–1218

Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells

  • Joseph W. Fay
  • A. Karolina Palucka
  • Sophie Paczesny
  • Madhav Dhodapkar
  • Dennis A. Johnston
  • Susan Burkeholder
  • Hideki Ueno
  • Jacques Banchereau
Original Article

Abstract

Between March 1999 and May 2000, 18 HLA-A*0201+ patients with metastatic melanoma were enrolled in a phase I trial using a dendritic cell (DC) vaccine generated by culturing CD34+ hematopoietic progenitors. This vaccine includes Langerhans cells. The DC vaccine was loaded with four melanoma peptides (MART-1/MelanA, tyrosinase, MAGE-3, and gp100), Influenza matrix peptide (Flu-MP), and keyhole limpet hemocyanin (KLH). Ten patients received eight vaccinations, one patient received six vaccinations, one patient received five vaccinations, and six patients received four vaccinations. Peptide-specific immunity was measured by IFN-γ production and tetramer staining in blood mononuclear cells. The estimated median overall survival was 20 months (range: 2–83), and the median event-free survival was 7 months (range: 2–83). As of August 2005, four patients are alive (three patients had M1a disease and one patient had M1c disease). Three of them have had no additional therapy since trial completion; two of them had solitary lymph node metastasis, and one patient had liver metastasis. Patients who survived longer were those who mounted melanoma peptide-specific immunity to at least two melanoma peptides. The present results therefore justify the design of larger follow-up studies to assess the immunological and clinical outcomes in patients with metastatic melanoma vaccinated with peptide-pulsed CD34-derived DCs.

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • Joseph W. Fay
    • 1
  • A. Karolina Palucka
    • 1
  • Sophie Paczesny
    • 1
  • Madhav Dhodapkar
    • 2
    • 3
  • Dennis A. Johnston
    • 4
  • Susan Burkeholder
    • 1
  • Hideki Ueno
    • 1
  • Jacques Banchereau
    • 1
  1. 1.Baylor Institute for Immunology ResearchDallasUSA
  2. 2.The Rockefeller UniversityNew YorkUSA
  3. 3.Hematology ServiceMemorial Sloan Kettering Cancer CenterNew YorkUSA
  4. 4.Department of StatisticsBaylor UniversityWacoUSA

Personalised recommendations